Hyperhomocysteinemia is associated with human coronary atherosclerosis through the reduction of the ratio of endothelium-bound to basal extracellular superoxide dismutase

Circulation Journal

Volumn 68, Issue 9, 2004, Pages 822-828

  Nihei, Shun Ichi ^a   Tasaki, Hiromi ^a   Yamashita, Kazuhito ^a   Ozumi, Kiyoshi ^a   Morishita, Tsuyoshi ^a   Tsutsui, Masato ^a   Okazaki, Masahiro ^a   Nakashima, Yasuhide ^a   Adachi, Tetsuo ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary artery disease; Endothelium; Extracellular superoxide dismutase; Homocysteine

Indexed keywords

HEPARIN; HOMOCYSTEINE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE;

BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; SUPEROXIDE DISMUTASE;

EID: 4544332854     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.822     Document Type: Article

References (36)

1. MuCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-122.
2. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet and cardiovascular disease: A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-182.
3. Upchurch GR Jr, Welch GN, Fabian AJ. Freedman JE, Johnson JL, Keaney JF, et al. Homocysteine decrease bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-17017.
4. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Harber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373.
5. Lentz SR, Salder JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914.
6. Roders GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-1916.
7. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-2879.
8. Nisinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in culture porcine aortic endothelial cell. J Clin Invest 1993; 92: 1381-1386.
9. Wilcken DEL, Wang WX, Adachi T, Hara H, Duarte N, Green K, et al. Relationship between homocysteine and Superoxide dismutase in homocystinuria. Arterioscler Thromb Vase Biol 2000; 20: 1199-1202.
10. Marklund SL. Human copper-containing Superoxide dismutase of high molecular weight. Proc Natl Acad Sci USA 1982; 79: 7634-7638.
11. Oury TD, Day BJ, Crapo JD. Extracellular Superoxide dismutase; A regulator of nitric oxide bioavailability. Lab Invest 1996; 75: 617-636.
12. Heistad DD. Mikamo Lecture: A radical view of the 'superfamily' of cardiovascular risk factors. Circ 2003; 67: 805-809.
13. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 2002; 66: 529-533.
14. Landmesser U, Merten R, Spiekermann S, Buttner K, Drexler H, Hornig B. Vascular extracellular Superoxide dismutase activity in patients with coronary artery disease-relation to endothelium-dependent vasodilation. Circulation 2000; 101: 2264-2270.
15. Horiucht M, Tsutsui M, Tasaki H, Morishita T, Suda O, Nakata S, et al. Upregulation of vascular extracellular Superoxide dismutase in patients with acute coronary syndrome. Arterioscler Thromb Vase Biol 2004; 24: 106-111.
16. Marklund SL, Nilsson P, Israelsson K, Schampi I, Peltonen M, Asplund K. Two variants of extracellular-superoxide dismutase: Relationship to cardiovascular risk factors in an unselected middle-aged population. J Intern Med 1997; 242: 514.
17. Juul K, Tybjarg-Hansen A, Marklund S, Heegaard NHH, Steffensen R, Sillesen H, et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 2004; 109: 59-65.
18. Adachi T, Yamada H, Yamada Y, Morihara N, Yamazaki N, Murakami T, et al. Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface. Biochem J 1996; 313: 235-239.
19. Gensini G. Stratification of coronary artery disease: Grading the severity of obstructive lesions. In: Braunwald E, editor. Heart disease. Philadelphia: WB Saunders Co; 1984; 343-344.
20. Tasaki H, Nakashima Y, Nandate H, Yashiro A, Kawashima T, Kuroiwa A. Comparison of serum of lipid values in variant angina pectoris and fixed artery disease with normal subjects. Am J Cardiol 1989; 63: 1441-1445.
21. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987; 27: 43-52.
22. Adachi T, Ohta H, Yamada H, Futenma A, Kato K, Hirano K. Quantitative analysis of extracellular Superoxide dismutase in serum and urine by ELlSA with monoclonal antibody. Clin Chim Acta 1992; 212: 89-102.
23. Karlson K. Marklund SL. Heparin-induced release of extracellular Superoxide dismutase to human blood plasma. Biochem J 1987; 242: 55-59.
24. Yamamoto M, Hara H, Adachi T. Effects of homocysteine on the binding of extracellular-superoxide dismutase to the endothelial cell surface. FEBS Lett 2000; 486: 159-162.
25. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.
26. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407-413.
27. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intake. JAMA 1995; 274: 1049-1057.
28. Nagai Y, Tasaki H, Takatsu H, Nihei S, Yamashita K, Toyokawa T, et al. Homocysteine inhibits angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 2001; 81: 726-731.
29. Nagai Y, Tasaki H, Miyamoto M, Nihei S, Kobayashi K, Yamashita K, et al. Plasma level of homocysteine is inversely associated with the development of collateral circulation in patients with single-vessel coronary artery disease. Circ J 2002; 66: 158-162.
30. Nonaka H, Tsujino T, Watari Y, Emoto N, Yokoyama M. Taurine prevents the decrease in expression and secretion of extracellular Superoxide dismutase induced by homocysteine: Amelioration of homocysteine-induced endoplasmic reticulum stress by taurine. Circulation 2001; 104: 1165-1170.
31. Chu Y, Iida S, Lund DD, Weiss RM, DiBona GF, Watanabe Y, et al. Gene transfer of extracellular Superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats: Role of heparin-binding domain. Circ Res 2003: 92: 461-468.
32. Watanabe Y, Chu Y, Andresen JJ, Nakane H, Faraci F, Heistad DD. Gene transfer of extracellular Superoxide dismutase reduces cerebral vasospasm after subaractinoid hemorrhage. Stroke 2003; 34: 434-440.
33. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
34. Welch GN, Upchurch GR, Farivar RS, Pigazzi A, Brecher P, Keaney JF, et al. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-κB-dependent transcriptional activation of NOS2. Proc Assoc Am Physicians 1998; 110: 22-31.
35. Takatsu H, Tasaki H, Kim HN, Ueda S, Tsutsui M, Yamashita K, et al. Overexpression of EC-SOD suppresses endothelial-cell-mediated LDL oxidation. Biochem Biophys Res Commun 2001; 286: 84-91.
36. Laukkanen M, Kivela A, Rissanen T, Rutanen J, Karkkainen MK, Brasen JH, et al. Adenovirus-mediated extracellular Superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation 2002; 106: 1999-2003.